Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819237 | 1.00 | RARB (0.36) | RARBLMNAKDM4CKDM4APHF8 | |
| SCHEMBL2816265 | 1.00 | RARB (0.36) | RARBLMNAKDM4CKDM4APHF8 | |
| SCHEMBL2819696 | 1.00 | RARB (0.36) | RARBLMNAKDM4CKDM4APHF8 | |
| SCHEMBL2821146 | 1.00 | RARB (0.36) | RARBLMNAKDM4CKDM4APHF8 | |
| SCHEMBL2821606 | 1.00 | RARB (0.36) | RARBLMNAKDM4CKDM4APHF8 | |
| SCHEMBL2935990 | 1.00 | RARB (0.36) | RARBLMNAKDM4CKDM4APHF8 | |
| Ammonia Solution, Strong SCHEMBL27326053 | 0.93 | RARB (0.33) | RARBLMNA | |
| SCHEMBL12610481 | 0.91 | ALDH1A1 (0.33) | RARBLMNABLMALDH1A1 | |
| SCHEMBL28002589 | 0.85 | LMNA (0.37) | RARBLMNAKDM4CKDM4APHF8 | |
| SCHEMBL29091867 | 0.83 | LMNA (0.36) | RARBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750712-A2 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | Mallinckrodt LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8604233-B2 | Lubricant composition, magnetic recording medium, and novel polyether compound | FUJIFILM CORPORATION (JP) | 2013-12-10 | — | — | US | disclosed |
| WO-2013033438-A2 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20100247971-A1 | LUBRICANT COMPOSITION, MAGNETIC RECORDING MEDIUM, AND NOVEL POLYETHER COMPOUND | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247971-A1 | LUBRICANT COMPOSITION, MAGNETIC RECORDING MEDIUM, AND NOVEL POLYETHER COMPOUND | MUC1, NEFM, CA13 | RARB 2438/4885LMNA 3717/4885KDM4C 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.